title: Oligometastatic Prostate Cancer.
abstract: The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatment to their primary tumour alongside 'metastasis-directed therapy' to the metastatic deposits. However, this regimen should be reserved to high-volume centres with quality assurance programmes and excellent outcomes. Patients should be made clear as to the uncertainty of benefit for this multi-site treatment strategy, and we await the publication of randomised controlled trials reporting in the next 5 years.
authors: Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Room 6607, Level 6, Headington, Oxford, OX3 9DU, UK.
authors: Daniel J
authors: DJ
authors: Stevens
authors: Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Room 6607, Level 6, Headington, Oxford, OX3 9DU, UK. prasanna.sooriakumaran@nds.ox.ac.uk.
authors: Prasanna
authors: P
authors: Sooriakumaran
mesh_terms: D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome
keywords: Oligometastatic; Prostate cancer